+------------------------------------------------------------------------------+
*WORLD DUTY FREE RATED NEW CONVICTION LIST-BUY AT GOLDMAN 2013-12-19 14:59:24.47 GMT
--JAMES LUDDEN
-0- Dec/19/2013 14:59 GMT
Precious metals stocks getting hit with weakness in underlying metals: GFI -3.8%, SLV -3.1%, AUY -2.7%, AU -2.6%, HMY -2.5%, KGC -2.4%, RGLD -2.3%, NEM -2.0%
Other news: GIG -8.5% announces proposed public offering of common stock (no amount given); CVM -8.5% announces proposed public offering of common stock and warrants (amount not given); VRTX -7.5% Vertex Pharm announces results of Phase 3 Study of Ivacaftor in people with CF who have the R117H Mutation; study did not meet its primary endpoint); CIE -7.2% announces targeted zones of its Aegean #1 exploratory well on Keathley Canyon Block 163 in the U.S. Gulf of Mexico did not encounter commercial hydrocarbons and operations are underway to plug and abandon the wellbore); IBN -5.3% (still checking for anything specific); SPCB -4.5% (priced 3 mln ordinary shares at $4.00 per share); FB -4.3% Facebook commences public offering of 70 mln shares of its Class A common stock; total of 27,004,761 shares are being offered by co, and a total of 42,995,239 shares are being offered by certain selling stockholders, including 41.35 mln shares offered by Mark Zuckerberg); WDR -1.6% (Waddell & Reed increases quarterly dividend by 21% to $0.34 per share from $0.28 per share); TSLA -0.7% (Tesla Motors Model S charging system may have started California garage fire, according to reports); MCD -0.3% (McDonald's Japan lowers revenue forecast to JPY 280 bln versus prior guidance of JPY 285 bln); UUUU -0.2% Energy Fuels enters into a Securities Purchase Agreement to sell all of its shares of Bayswater Uranium to Mega Uranium in exchange for 1.75 mln newly issued common shares of Mega)
M&A news: BMY +1% (BMY to sell its diabetes business to AstraZeneca (AZN); raises Quarterly div by $0.01 to $0.36 per share); BAYRY +0.1% (Bayer AG plans to acquire Norwegian pharmaceutical co Algeta for NOK 362 per share in cash; implies equity value of NOK 17.6 bln (EUR 2.1 bln)
Other news: ALIM +90% (co and FDA Enter Into Labeling Discussions for ILUVIEN, Agree Advisory Committee No Longer Necessary); PSDV +58% (partnered with ALIM, co and FDA Enter Into Labeling Discussions for ILUVIEN, Agree Advisory Committee No Longer Necessary; CDTI +29% (announced that it has received two significant emission reduction product verifications from the U.S. Environmental Protection Agency (the "EPA") for use in heavy duty highway truck engines and off-road engines); OXBT +8.5% (provides a business review and update in conjunction with filing of 2Q2014 financials; in 2014, co anticipates enrolling first patient in the Phase 3 trial for levosimendan in cardiac surgery patients at risk for developing LCOS in July 2014); CCIH +8.3% (still checking); HYGS +8.0% (selected as a participating partner in a DOE project award to supply hydrogen fuel cell modules to the Center for Transportation and the Environment); GILT +7.6% (awarded a project valued at $30 mln as part of the Integracion Amazonica Loreto; awarded $99-million project from Colombia's MINTIC); USU +7.3% (was informed that Department of Energy Prepared to Extend American Centrifuge RD&D Program Three Months) STNG +5.0% (still checking); PERI +4.6% (still checking); TRLA +4.0% (S.A.C. Capital discloses 5.2% passive stake in 13G filing); COG +2.7% (announces agreement to provide natural gas to the Dominion Cove Point LNG Terminal); BBRY +1.3% (announced two appointments that strengthen the Company's strategy, marketing and operations); HALO +2.1% (still checking); CIEN +1.7% (ollowing favorable mention on Mad Money); TSL +0.3% (Trina Solar has been chosen as the sole supplier of 25 MW of modules to Phase III of the 75 MW Bangchak Solar Energy Project in Thailand)
Analyst comments: RMTI +7.9% (Chardan Capital Markets Initiated Coverage with a Buy and $22 tgt); CHTP +2.5% (initiated with a Mkt Outperform at JMP Securities)
*METSO METSO LOWERS EBITA GUIDANCE FOR PULP, PAPER, POWER
Gapping down: SMTC -18.0%, GIG -8.5%, CVM -8.5%, RAD -8.0%, VRTX -7.5%, SPCB -4.5%, FB -4.3%, ACN -3.0%, APOG -2.5%, WDR -1.6%, PIR -1.0%, MLHR -0.8%, TSLA -0.7%, MCD -0.3%, UUUU -0.2%, APC -0.2%, OAKS -0.1%, DISH -0.1%
+------------------------------------------------------------------------------+
BN 12/19 12:26 *FRENCH COMPETITION BODY FINES SCHERING-PLOUGH EU15.3 MLN
+------------------------------------------------------------------------------+
French Competition Body Fines Schering-Plough EU15.3m 2013-12-19 12:36:20.53 GMT
By Steve Rhinds Dec. 19 (Bloomberg) -- The national competition authority said the co. offered ‘unjustified’ discounts to pharmacists in an attempt to limit sales of a generic version of its Subutex treatment. * Parent co. Merck is also fined EU414,000 for collusion and Subutex manufacturer Reckitt Benckiser was fined EU318,000, the competition authority said in a statement on its website * Schering-Plough and Reckitt Benckiser formed a joint plan in 2005 to minimize sales of generic rivals, the authority says
Link to competition authority statement (in French): http://tinyurl.com/pqzvpbc
Link to Company News:{RB/ LN <Equity> CN <GO>} Link to Company News:{MRK US <Equity> CN <GO>}
For Related News and Information: First Word scrolling panel: {FIRST<GO>} First Word newswire: {NH BFW<GO>}
To contact the editor responsible for this story: Steve Rhinds at +33-1-5365-5072 or srhinds@bloomberg.net